Showing 4301-4310 of 6036 results for "".
- The Lancet Publishes 24-Month Results from Phase 3 Studies of Syfovre for GAhttps://modernod.com/news/the-lancet-publishes-24-month-results-from-phase-3-studies-of-syfovre-for-geographic-atrophy/2481901/Apellis Pharmaceuticals announced that The Lancet has published 24-month results from the phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan injection)
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLshttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols/2481897/Bausch + Lomb announced the launch of the enVista Aspire monofocal and toric IOLs in the United States. The enVista Aspire IOLs featured B+L's Intermediate Optimized (IO) optics, which are designed for a broader depth of focus, with the benefits of the enVista platform to address patient
- FDA Finds 'Substantive' Issues in Aldeyra’s NDA for Reproxalap for Dry Eye Diseasehttps://modernod.com/news/fda-finds-substantive-issues-in-aldeyras-reproxalap-drug-candidate-for-dry-eye-disease/2481895/Aldeyra Therapeutics was dealt a major setback this week as the FDA identified "substantive review issues" in the company’s new drug application for dry-eye disease treatment candidate reproxalap. In a US securities
- Optos Unveils New Retinal Imaging Technology at Euretinahttps://modernod.com/news/optos-unveils-new-retinal-imaging-technology-at-euretina/2481893/Optos announced advances to its ultra-widefield multimodal retinal imaging at its satellite symposia at the Euretina congress in Amsterdam. Optos’ devices capture ultra-widefield (UWFTM) high-resolution optomap images of 200 degress of the retina in a sing
- Baxter Launches Digital Image Capture Capability of Panoptic Plus Ophthalmoscopehttps://modernod.com/news/baxter-launches-digital-image-capture-capability-of-panoptic-plus-ophthalmoscope/2481891/Baxter International announced the launch of digital image capture capability for eye exams using its existing Welch Allyn PanOptic Plus Ophthalmoscope. The iExaminer Pro System adds a key technology to routine eye exams, designed to help advance healthcare professio
- Tilak Healthcare Raises €10 Million to Continue Growing Its Ophthalmological Telemedicine Offeringhttps://modernod.com/news/tilak-healthcare-raises-eur10-million-to-continue-growing-its-leading-ophthalmological-telemedicine-offering/2481890/Tilak Healthcare has raised €10 million in a funding to accelerate the roll-out of OdySight in France and abroad, and to develop new solutions for other medical conditions. OdySight is the first remote monitoring system for ophthalmic conditions combined with a gaming interface designed
- Heidelberg Engineering Receives FDA Clearance for Anterion Platformhttps://modernod.com/news/heidelberg-engineering-announces-fda-clearance-of-anterion-platform/2481889/Heidelberg Engineering has received FDA clearance of its Anterion platform, designed to improve anterior segment diagnostics and streamline practice workflow. “Building upon our previous CE-marking, we are thrilled that the Anterion platform is
- Sight Sciences Presents Phase 1 Results of the SAHARA Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Diseasehttps://modernod.com/news/sight-sciences-presents-phase-1-results-of-the-sahara-trial-comparing-tearcare-to-restasis-for-the-treatment-of-dry-eye-disease/2481888/Sight Sciences announced the presentation of the full phase 1 results from the SAHARA randomized controlled trial, demonstrating that interventional eyelid procedures for dry eye disease enabled by TearCare technology were superior at all measured time points to Restasis prescription eye dro
- OKYO Pharma Announces Filing of an IND Application for OK-101 to Treat Neuropathic Corneal Painhttps://modernod.com/news/okyo-pharma-announces-filing-of-an-ind-application-for-ok-101-to-treat-neuropathic-corneal-pain/2481882/OKYO Pharma announced that it filed an investigational new drug (IND) application with the FDA for the development of OK-101 to treat Neuropathic Corneal Pain (NCP). Study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA. There is no FDA-appr
- Two-Year Results of Eylea HD (Aflibercept 8 mg) from PULSAR Trial for Wet AMD Presented at Euretinahttps://modernod.com/news/two-year-results-of-eylea-hd-aflibercept-8-mg-from-pulsar-trial-presented-at-euretina/2481870/Regeneron announced the first presentation of positive 2-year (96 weeks) results from the PULSAR trial investigating Eylea HD (aflibercept) injection 8 mg with 12- and 16-week dosing regimens, compared to Eylea (aflibercept) injection, in patients with wet age-related macular degenerati